Paul A Sprengeler

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

Stephen K Burley, Spencer Emtage, Shane Atwell, 2009, Molecular Cancer Therapeutics.

Structure-guided design of peptide-based tryptase inhibitors.

Yang Liu, James W Janc, J. R. Somoza, 2006, Biochemistry.

Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).

Erik Verner, James W Janc, J. R. Somoza, 2004, Journal of Molecular Biology.

Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.

Louis-David Cantin, Lawrence C Kuo, Ralph Hirschmann, 2003, Journal of medicinal chemistry.

The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain.

J. R. Somoza, M. Mcgrath, B. Katz, 2003, Structure.